Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday - Microsoft (NASDAQ:MSFT)

Analysts updated price targets for several companies. Piper Sandler raised Microsoft's target to $610, maintaining an Overweight rating. Other notable changes include Carmax, Accelerant, Jack Henry, Moderna, Grocery Outlet, Hinge Health, Aytu Biopharma, NetApp, and Ferrari.

Original reporting
Published Sep 30, 2026, 12:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 12:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$KMX
Bullish
medium confidence
Mentioned
$KMX · $ARX · $JKHY · $MRNA · $GO · $HNGE
Relevance
5/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$KMXBullishLow
01

Why it matters

While the revisions provide fresh data points, they are largely reactionary and do not constitute a primary market‑moving event.

02

Market read

Analyst target updates offer modest guidance cues but lack a decisive catalyst for immediate trading decisions.

03

What to watch

Macro backdrop and upcoming earnings season could outweigh individual analyst revisions.

Relevance 5/10Novelty 5/10Timing: post‑market Tuesday

Background

The article aggregates recent analyst price‑target adjustments for a set of U.S. stocks, including Microsoft, following the latest earnings season.

Company-level read

Ticker impact

$KMXBullishMedium confidence
Context

BNP Paribas raised Carmax price target to $48, indicating potential upside.

Expected impact

likely upward pressure as investors price in higher expectations

Evidence & confidence

Analyst upgrade and higher target often precede price gains.

$ARXBearishMedium confidence
Context

TD Cowen cut Accelerant target to $20.25, indicating downside risk.

Expected impact

potential pressure as market absorbs lower expectations

Evidence & confidence

Downgrade and lower target typically lead to short-term sell pressure.

$JKHYBearishMedium confidence
Context

Morgan Stanley reduced Jack Henry target to $158, implying modest downside.

Expected impact

possible modest decline

Evidence & confidence

Analyst cut often translates to near‑term price adjustment.

$MRNANeutralLow confidence
Context

Citigroup lifted Moderna target to $80 but downgraded rating to Sell, mixed signal.

Expected impact

limited movement pending market interpretation

Evidence & confidence

Conflicting signals may offset each other.

$GOBullishMedium confidence
Context

B of A raised Grocery Outlet target to $15, indicating upside.

Expected impact

likely upward pressure

Evidence & confidence

Analyst upgrade often precedes price gains.

$HNGEBullishMedium confidence
Context

Needham raised Hinge Health target to $115, maintaining Buy rating.

Expected impact

potential upside

Evidence & confidence

Higher target aligns with bullish sentiment.

$AYTUBullishLow confidence
Context

Ascendiant Capital lifted Aytu Biopharma target to $15, modest increase.

Expected impact

minor upward pressure

Evidence & confidence

Small change may have limited market impact.

$MSFTBullishMedium confidence
Context

Piper Sandler raised Microsoft target to $610, maintaining Overweight rating.

Expected impact

potential upward pressure

Evidence & confidence

Analyst target increase for a mega‑cap often supports price gains.

Market effects

Analyst target revisions across consumer, tech, and biotech may slightly shift sector sentiment.

U.S. equity market, no specific regional effect.

Limited; primarily U.S. listed companies.

Counterpoint

Target changes may be premature; price moves could be muted if broader market sentiment dominates.

Key entities

  • Microsoft Corp

    Subject of a target raise to $610.

  • Piper Sandler

    Raised Microsoft target.

Related articles

$AYTUHighAI 9/10

Rosemont to acquire Aytu BioPharma for $2.70 per share

Rosemont Pharmaceuticals will acquire Aytu BioPharma (NASDAQ:AYTU) for $2.70 per share, a 41.1% premium over Aytu's 30-day average. The deal, approved by Aytu's board, is expected to close by late 2026. Aytu focuses on central nervous system disease treatments. Rosemont is backed by private equity firm Inflexion.

$AYTUHigh

Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results

AYTU BIOPHARMA, INC (AYTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results Due to the pending merger with Rosemont Pharmaceuticals Holdings, Inc., the Company will not be holding an earnings conference call to discuss its financial results DENVER, CO / Novemb

$WFCMed

Days after Microsoft and the FAA went dark, Chase and Wells Fargo customers can’t get to their money

Chase and Wells Fargo customers reported widespread outages on Monday, affecting websites, apps, ATMs, and in-person systems. Chase acknowledged a technical issue but stated funds were accessible. Other banks, including Bank of America and U.S. Bank, also saw outage reports. The cause remains unclear, and no connection to recent Microsoft or FAA outages has been established.

$MSFTMed

Microsoft Apologises for Massive Global Outage and Reveals Three Factors Behind the Widespread Disruption

Microsoft apologized for a global Microsoft 365 outage on 12 November, disrupting Exchange Online and related services. The outage lasted nearly 24 hours and was caused by a dormant software defect, increased traffic from Teams, and reduced server capacity. Microsoft said there was no cyber activity involved and most services were restored by 13 November. The outage affected users, including some UK police forces and OpenAI's Microsoft 365 connector.